NJ Bio, Inc. is thrilled to be recognized as the Runner-Up in the Best CRO (Contract Research Organization) category at the 12th Annual World ADC Awards in San Diego. This distinction celebrates the company’s excellence, innovation, and impact in the ADC space.
NJ Bio congratulates all winners and nominees of the 12th Annual World ADC Awards and extends its gratitude to the community for recognizing the company’s contributions to the field of ADC development.
Being named Runner-Up this year marks the sixth time NJ Bio has been recognized at the World ADC Awards, following four consecutive wins in previous years. This continued recognition is a testament to the team’s unwavering commitment, technical expertise, and the trust placed in the company by clients and partners worldwide. NJ Bio remains dedicated to advancing the ADC field by delivering high-quality, chemistry-driven solutions that support clients from discovery through early-phase clinical development.
Building on this achievement, the company continues to expand its scientific capabilities and service offerings across complex conjugation, advanced analytics, and early-stage clinical development, with translational research recently added to further strengthen its support for drug discovery programs. NJ Bio remains committed to driving innovation and advancing next-generation ADC therapeutics that improve patient outcomes worldwide.